Epigenetic Therapy Showed Muscle Gains in Phase I/II Trial
The gene-modulating treatment silenced a faulty gene, reversing expected muscle loss in early testing.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you trust that new gene therapies are successfully improving lives for patients with muscular conditions?
Epicrispr Biotechnologies has reported updated Phase I/II clinical trial results for its epigenetic therapy, EPI-321. The gene-modulating treatment demonstrated an increase in muscle volume and strength in a six-patient cohort where natural history predicted a decline.
Why it matters
This development marks a potential shift toward non-destructive gene modulation for muscular disorders. By targeting expression rather than editing the genome, the therapy aims to halt disease progression without introducing permanent DNA changes.
Patients receiving 2x10 or 4x10 vg/kg doses showed a 4.1% improvement in upper body muscle strength compared to a 0.3% decline in natural history. The treatment utilizes an AAV vector to silence DUX4 gene expression.
The players
Epicrispr Biotechnologies
A biotech startup focused on epigenetic gene-modulating therapies delivered via viral vectors.
The details
The therapy functions via an AAV vector — a modified harmless virus used as a delivery vehicle — to target the DUX4 gene. By modulating this gene, the treatment suppresses its expression without altering the underlying DNA sequence. In the six-patient cohort, this approach resulted in an 8.1% increase in elbow extension strength and a 3.2% increase in elbow extensor lean muscle volume.
Timeline
June 2026: Epicrispr reported interim findings from three patients.
August 2026: The company raised $90 million in Series C funding.
October 5, 2026: Phase I/II data was presented at the World Muscle Society congress.
Second half of 2027: Epicrispr plans to present twelve-month study data.
The Tech Race
This trial data positions Epicrispr within an competitive landscape of gene-silencing developers aiming to treat muscular conditions without permanent genome editing. The company is now preparing to move its platform into pivotal testing following the presentation at the World Muscle Society congress.
The therapy is currently in clinical trial stages and is not available for patients outside of study cohorts. Future accessibility will depend on the successful completion of pivotal testing and subsequent regulatory approval.
The takeaway
The study suggests that non-destructive gene silencing can translate into measurable muscle performance gains. Readers should track the company’s transition to pivotal testing, which will serve as the primary indicator for the therapy's potential path to market.
What happens next
Epicrispr is scheduled to release twelve-month data from all study participants in the second half of 2027, followed by an planned transition into pivotal clinical testing.
Further reading
For broader trends in gene-modulating treatments, visit Biotech.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that new gene therapies are successfully improving lives for patients with muscular conditions?
